Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACC 2017: Double-Whammy Trial Data Boost For Philips' iFR

Executive Summary

Results from the iFR SWEDEHEART and DEFINE-FLAIR trials, both presented at this month's American College of Cardiology Scientific Sessions in Washington, DC, show that coronary revascularization guided by instantaneous wave-free ratio measurement is non-inferior to fractional flow reserve measurement in guiding coronary revascularization

You may also be interested in...



Market Intel: Increasingly Less-Invasive Diagnostic Techs To Disrupt Interventional Cardio Market

The global market for diagnostic and guided interventional cardiology products is expected to reach $4.8bn by 2021, and is driven in large part by the rising elderly population and increasing burden of cardiovascular disease (CVD). Meddevicetracker expects that intracardiac echocardiography (ICE), guide wire-based intravascular stenosis assessment (FFR) and optical coherence tomography (OCT) systems will drive overall market growth, given their high demand, which is supported by clinical evidence needed to bring cost savings and improved outcomes. Physicians' preference for using noninvasive and minimally invasive diagnostic techniques in cases where results are inconclusive is also changing the landscape of innovation. In this feature, we'll take a closer look at the overall market and its regional perspective, the competitive landscape of the three fastest-growing segments ICE, FFR and OCT, and the latest emerging technologies, as well as provide insight into what physicians think of these technologies.

EuroPCR 2017: TAVR Continues To Beat Surgery; Bioabsorbable Stents Not Going Away

The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.

Philips splashes $1bn on Volcano

Imaging giant Philips is hoping acquisitions will help it out of its current slump, betting €800m ($1bn) on cardiovascular device specialist Volcano. The deal is worth $18 per Volcano share, a 57% premium over its closing price of $11.49 on 16 December, the day the acquisition was announced.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT104631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel